To cite this article: Teruel R, Pé rez-Sá nchez C, Corral J, Herranz MT, Pé rez-Andreu V, Saiz E, García-Barberá N, Martínez-Martínez I, Roldá n V, Vicente V, Ló pez-Pedrera C, Martínez C. Identification of miRNAs as potential modulators of tissue factor expression in patients with systemic lupus erythematosus and antiphospholipid syndrome. J Thromb Haemost 2011; 9: 1985-92.Summary. Background: Tissue factor (TF) is the main initiator of the coagulation cascade and elements that may upregulate its expression might provoke thrombotic events. Systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS) are autoimmune diseases characterized by a high TF expression in monocytes. Objectives: To examine the role of microRNAs (miRNAs) in TF expression and to evaluate their levels in SLE and APS patients. Methods: An in silico search was performed to find potential putative binding sites of miRNAs in TF mRNA. In vitro validation was performed transfecting cells expressing TF (THP-1 and MDA-MB-231) with oligonucleotide miRNA precursors and inhibitors. Additionally, reporter assays were performed to test for the binding of miR-20a to TF mRNA. Levels of miRNAs and TF were measured by quantitative (qRT-PCR) in patients with APS and SLE. Results: Overexpression of miRNA precursors, but not inhibitors, of two of the members of cluster miR-1792, for example miR-19b and miR-20a, in cells expressing TF decreased TF mRNA, protein levels, and procoagulant activity between 30% and 60%. Reporter assays showed that miR-20a binds to TF mRNA. Finally, we measured levels of miR-19b and miR-20a in monocytes from patients with APS and SLE and observed significantly lower miRNAs levels in comparison with healthy subjects inversely correlated with the levels of TF. Conclusions: Down-regulation of miR-19b and miR-20a observed in patients with SLE and APS could contribute to increased TF expression and thus provoke the hypercoagulable state characteristic of these patients.
MicroRNAs markedly affect the immune system, and have a relevant role in CVD and
autoimmune diseases. Yet, no study has analyzed their involvement in
atherothrombosis related to APS and SLE patients. This study intended to: 1)
identify and characterize microRNAs linked to CVD in APS and SLE; 2) assess the
effects of specific autoantibodies. Six microRNAs, involved in atherothrombosis
development, were quantified in purified leukocytes from 23 APS and 64 SLE patients,
and 56 healthy donors. Levels of microRNAs in neutrophils were lower in APS and SLE
than in healthy donors. Gene and protein expression of miRNA biogenesis-related
molecules were also reduced. Accordingly, more than 75% of identified miRNAs by
miRNA profiling were underexpressed. In monocytes, miR124a and -125a were low, while
miR-146a and miR-155 appeared elevated. Altered microRNAs’ expression was
linked to autoimmunity, thrombosis, early atherosclerosis, and oxidative stress in
both pathologies. In vitro treatment of neutrophils, monocytes, and ECs with
aPL-IgG or anti-dsDNA-IgG antibodies deregulated microRNAs expression, and decreased
miRNA biogenesis-related proteins. Monocyte transfections with pre-miR-124a and/or
-125a caused reduction in atherothrombosis-related target molecules. In conclusion,
microRNA biogenesis, significantly altered in neutrophils of APS and SLE patients,
is associated to their atherothrombotic status, further modulated by specific
autoantibodies.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.